Heat-stable ritonavir approved, ending treatment stranglehold for people living with HIV/AIDSread more
Make It Happen Campaign Update: UNITAID Board still discussing finer details of the Patent Pool Entity read more
New European Parliament Working Group on Innovation & Access launches with support of Access Campaign read more
U.S. health care legislation could limit access read more
MSF responds to World Health Organization’s new HIV treatment guidelines read more
MSF sends letter to EU Ministers of Health regarding antibiotic resistance read more
 |
 |
|
 |
Company: Sequoia Pharmaceuticals, Inc.
Headquarters: Gaithersburg, USA
We want Sequoia Pharmaceuticals to put these drug patents in the pool:
SPI-452
Currently in clinical trials
SPI-452 is a new class of booster drug that when given with some antiretrovirals, increases their drug levels in the blood to make them more effective. This drug is still at the early stages of development but it would be important to get the patents in the pool - at the moment, there is only one other booster available, and it’s important to have more options.
People Living with HIV/AIDS: India must not sacrifice us in trade agreement with Europe
Indian Court Gives Boost to Access to Medicines As Latest Appeal By Bayer is Rejected
UNITAID Patent Pool: Innovative Initiative Designed to Boost Access to Medicines is Adopted
MSF Clinical Officer Olesi Ellemani Pasulani's reflections on AIDS treatment in Malawi
Living with MDR TB: 'Expert Client' Nonkululeko Mamba's Story
MDR TB Treatment in Cambodia: A Catalyst for Change
